Dell Technologies and the University of Limerick (UL) are combining their resources to advance cancer research using AI.
Dell Technologies and the University of Limerick (UL) are combining resources and using AI to advance cancer research.
Dell created an AI platform for the University that delivers high performance computing power to accelerate oncology and precision medicine research.
The partnership aims to assist researchers to rapidly accelerate biomarker testing for cancer. The AI platform uses digital twin technology with cancer patient data to improve diagnosis and treatment capabilities.
Multi-Cloud Ecosystem
The platform sits within the Digital Cancer Centre’s multi-cloud ecosystem. It is powered by Dell’s latest storage arrays and Dell PowerEdge servers optimised for AI to produce cancer patient digital twins for better diagnostics.
The new AI platform aims to help researchers gain a better understanding of how to treat patients with B-cell lymphoma, and develop personalised therapies based on a person’s tumour characteristics.
By using emerging technologies, researchers at the Digital Pathology Unit at the University of Limerick’s Digital Cancer Research Centre can also better understand the pathogenesis of these malignancies and develop novel therapeutic approaches.
The researchers are particularly interested in the possibility that collagen within the tumour ‘microenvironment’ can cause the cancerous cells to spread around the body and to the central nervous system.
Having already identified novel ways to block collagen, the research could lead to new treatments to cure patients before the tumour spreads.
Precision Treatments
Professor of Molecular Pathology at University of Limerick and Director of the Digital Pathology Unit at the Digital Cancer Research Centre Paul Murray said: “Through our partnership with the Dell Technologies team, we will be able to advance our knowledge of how cells go wrong during cancer development and find new ways to diagnose and treat cancer patients.
“This is the beginning of a very exciting research project for the team here at the University of Limerick’s Digital Cancer Research Centre, and we’re looking forward to accelerating this project with the digital support and insights from the team at Dell Technologies.”
Catherine Doyle, Managing Director of Dell Technologies, Ireland, said: “The new AI-driven platform developed by Dell Technologies will ultimately help researchers and healthcare professionals deliver precision treatments for patients with B-cell lymphoma by understanding how it develops.
“Through the creation of these digital twins, the University of Limerick and Dell are taking clinical research to a new level. Together, we are harnessing the power of data through new technologies to benefit patients and healthcare professionals globally.”